Immature platelets as a biomarker for disease severity and mortality in COVID‐19 patients
| Autor: | Daniel Welder, Taha Bat, Haekyung Jeon-Slaughter, Weina Chen, Ibrahim F. Ibrahim, Bilal Ashraf, Sung-Hee Choi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Blood Platelets
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) immature platelet Immature Platelet law.invention law Internal medicine Severity of illness Medicine Humans Platelet Thrombopoiesis reticulated platelets Covid‐19 business.industry Platelet Count SARS-CoV-2 COVID-19 Hematology Intensive care unit IPF Biomarker (medicine) biomarker Viral disease business Research Paper |
| Zdroj: | British Journal of Haematology |
| ISSN: | 1365-2141 0007-1048 |
| Popis: | Summary COVID‐19, caused by SARS‐CoV‐2, is a contagious life‐threatening viral disease that has killed more than three million people worldwide to date. Attempts have been made to identify biomarker(s) to stratify disease severity and improve treatment and resource allocation. Patients with SARS‐COV‐2 infection manifest with a higher inflammatory response and platelet hyperreactivity; this raises the question of the role of thrombopoiesis in COVID‐19 infection. Immature platelet fraction (IPF, %) and immature platelet counts (IPC, ×109/l) can be used to assess thrombopoiesis. This study investigates whether the level of thrombopoiesis correlates with COVID‐19 severity. A large cohort of 678 well‐characterized COVID‐19 patients was analyzed, including 658 (97%) hospitalized and 139 (21%) admitted to the intensive care unit (ICU). Elevated percentage IPF at presentation was predictive of length of hospitalization (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text